GlassScriptPhysician profile
Rene Kessler
NPI 1356909329
$2,187.24
in general payments reported to CMS, 2019-2025
20 companies · $1,753 in 2025
The $1,753 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $115 · 2023: $73.00 · 2024: $246 · 2025: $1,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $324.70 | 2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $268.95 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $211.65 | 2024-2025 | Lokelma, Breztri, Airsupra |
| Exact Sciences Corporation | $201.08 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $182.99 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $176.08 | 2025 | |
| Abbvie INC. | $130.40 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.40 | 2024-2025 | Jardiance |
| Vertex Pharmaceuticals Incorporated | $73.00 | 2023 | |
| Amgen INC. | $68.23 | 2024-2025 | Evenity, Repatha, Otezla |
| Verona Pharma, INC. | $62.42 | 2025 | Ohtuvayre |
| Kowa Pharmaceuticals America, INC. | $61.14 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $56.33 | 2024-2025 | Rotarix, Bexsero, Penmenvy |
| Sumitomo Pharma America, INC. | $54.67 | 2025 | Gemtesa |
| Hologic Sales and Service, LLC | $53.11 | 2024-2025 | Aptima |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $48.64 | 2025 | |
| Dexcom, INC. | $47.11 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $29.31 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Krystal Biotech INC | $15.94 | 2025 | Vyjuvek |
| Cequr Corporation | $14.09 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Kessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.